Trial Profile
Pentaglobin as Early Adjuvant Treatment for Febrile Neutropenia in Acute Leukemia or Allogeneic Hematopoietic Stem Cell Transplant Patients Colonized by Carbapenem-resistant Enterobacteriaceae (CRE) or Pseudomonas Aeruginosa (PA)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 May 2023
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Febrile neutropenia
- Focus Therapeutic Use
- Acronyms PENTALLO
- 09 May 2023 Planned End Date changed from 1 Dec 2023 to 30 Jun 2025.
- 09 May 2023 Planned primary completion date changed from 30 Apr 2023 to 30 Jun 2024.
- 08 Aug 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2023.